If there was ever a time for this pic, it’s now.
Bud’s official statement:
“Major League Baseball has worked diligently with the Players Association for more than a decade to make our Joint Drug Program the best in all of professional sports. I am proud of the comprehensive nature of our efforts – not only with regard to random testing, groundbreaking blood testing for human Growth Hormone and one of the most significant longitudinal profiling programs in the world, but also our investigative capabilities, which proved vital to the Biogenesis case. Upon learning that players were linked to the use of performance-enhancing drugs, we vigorously pursued evidence that linked those individuals to violations of our Program. We conducted a thorough, aggressive investigation guided by facts so that we could justly enforce our rules.
“Despite the challenges this situation has created during a great season on the field, we pursued this matter because it was not only the right thing to do, but the only thing to do. For weeks, I have noted the many players throughout the game who have strongly voiced their support on this issue, and I thank them for it. I appreciate the unwavering support of our owners and club personnel, who share my ardent desire to address this situation appropriately. I am also grateful to the Professional Baseball Athletic Trainers Society and our club physicians, who were instrumental in the banning of amphetamines and whose expertise remains invaluable to me. As an institution, we have made unprecedented strides together.
“It is important to point out that 16,000 total urine and blood tests were conducted on players worldwide under MLB Drug Programs in 2012. With the important additions of the hGH testing and longitudinal profiling this season, we are more confident than ever in the effectiveness of the testing program. Those players who have violated the Program have created scrutiny for the vast majority of our players, who play the game the right way.
“This case resoundingly illustrates that the strength of our Program is not limited only to testing. We continue to attack this issue on every front – from science and research, to education and awareness, to fact-finding and investigative skills. Major League Baseball is proud of the enormous progress we have made, and we look forward to working with the players to make the penalties for violations of the Drug Program even more stringent and a stronger deterrent.
“As a social institution with enormous social responsibilities, Baseball must do everything it can to maintain integrity, fairness and a level playing field. We are committed to working together with players to reiterate that performance-enhancing drugs will not be tolerated in our game.”
New Mariners general manager Jerry Dipoto has kept pretty busy in his short time on the job and Bob Dutton of the Tacoma News Tribune reports that free agent outfielder Nori Aoki could be his next target. The club recently pursued a trade for Marlins outfielder Marcell Ozuna, but the asking price has them looking at alternatives.
Aoki, who turns 34 in January, has hit .287 with a .353 on-base percentage over four seasons since coming over from Japan. He was having a fine season with the Giants this year prior to being shut down in September with lingering concussion symptoms.
The Giants decided against picking up Aoki’s $5.5 million club option for 2016 earlier this month, but he should still do pretty well for himself this winter assuming he’s feeling good.
It was reported Sunday that free agent right-hander Johnny Cueto had turned down a six-year, $120 million contract from the Diamondbacks. He’s hoping to land a bigger deal this winter and ESPN’s Jerry Crasnick has heard some chatter about what he’s looking for.
Jordan Zimmermann finalized a five-year, $110 million contract with the Tigers today, which works out to $22 million per season. Arizona’s offer to Cueto checked in at $20 million per season. A six-year offer to Cueto at the same AAV (average annual value) as Zimmermann would put him at $132 million, which is still a little shy of the figure stated by Crasnick. Of course, Cueto owns a 2.71 ERA (145 ERA+) over the last five seasons compared to a 3.14 ERA (123 ERA+) by Zimmermann during that same timespan, so there’s a case to be made that he should get more. Still, he’s the clear No. 3 starter on the market behind David Price and Zack Greinke.
CBS Sports’ Jon Heyman reports that the Dodgers, Giants, Red Sox, and Cubs are among the other teams who have interest in Cueto. One variable in his favor is that he is not attached to draft pick compensation, as he was traded from the Reds to the Royals during the 2015 season.
The rebuilding Braves have already been active on the trade market and they might not be done, as CBS Sports’ Jon Heyman reports that right-hander Shelby Miller has been a very popular name. In fact, around 20 teams have checked in.
Nothing is considered close and the Braves have set a very high asking price, mostly centered around offense. They asked for right-hander Luis Severino in talks with the Yankees and would expect outfielder Marcell Ozuna among other pieces from the Marlins. The Diamondbacks and Giants are among the other interested clubs.
Miller is under team control through 2018, so there’s not necessarily a sense of urgency to move him, but anything is possible with the way the Braves are doing things right now. The 25-year-old is coming off a year where he went 6-17, but that was about really rotten luck more than anything else, as he had a fine 3.02 ERA and 171/73 K/BB ratio over 205 1/3 innings. The Braves gave him the worst run support of any starter in the majors.
Jenrry Mejia appeared in just seven games this past season due to a pair of suspensions for performance-enhancing drugs, but Adam Rubin of ESPN New York reports that the Mets are expected to tender him a contract for 2016.
While the Mets were vocal about their disappointment in Mejia’s actions, it makes sense to keep him around as an option. Had he played a full season in 2015, he would have earned $2.595 million. He’s arbitration-eligible for the second time this winter and figures to receive a contract similar to his 2015 figure, but he’ll only be paid for the games he plays. He still has 100 games to serve on his second PED suspension, which means that he’ll only be paid for 62 games in 2016. This likely puts his salary closer to $1 million, which is a small price to pay for someone who could prove useful during the second half and beyond. He also won’t count toward the team’s 40-man roster until he’s active.
Mejia, who turned 26 in October, owns a 3.68 ERA in the majors and saved 28 games for the Mets in 2014. He’s currently pitching as a starter in the Dominican Winter League.